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Abstract
Autoimmune gastritis is often suspected for its hematologic findings, and rarely the diagnosis is made for the presence of
gastrointestinal symptoms. Aims of this cross-sectional study were to assess in a large cohort of patients affected by autoimmune
gastritis the occurrence and the pattern of gastrointestinal symptoms and to evaluate whether symptomatic patients are
characterized by specific clinical features.
Gastrointestinal symptoms of 379 consecutive autoimmune gastritis patients were systematically assessed and classified
following Rome III Criteria. Association between symptoms and anemia pattern, positivity to gastric autoantibodies, Helicobacter
pylori infection, and concomitant autoimmune disease were evaluated.
In total, 70.2% of patients were female, median age 55 years (range 17–83). Pernicious anemia (53.6%), iron deficiency anemia
(34.8%), gastric autoantibodies (68.8%), and autoimmune disorders (41.7%) were present. However, 56.7% of patients complained
of gastrointestinal symptoms, 69.8% of them had exclusively upper symptoms, 15.8% only lower and 14.4% concomitant upper and
lower symptoms. Dyspepsia, subtype postprandial distress syndrome was the most represented, being present in 60.2% of
symptomatic patients. Univariate andmultivariate analyses showed that age<55 years (OR 1.6 [CI:1–2.5]), absence of smoking habit
(OR 2.2 [CI:1.2–4]), and absence of anemia (OR 3.1 [CI:1.5–6.4]) were independent factors associated to dyspepsia.
Autoimmune gastritis is associated in almost 60% of cases with gastrointestinal symptoms, in particular dyspepsia. Dyspepsia is
strictly related to younger age, no smoking, and absence of anemia.
Abbreviations: AG = autoimmune gastritis, EPS = epigastric pain syndrome, GERD = gastro-esophageal reflux disease, GI =
gastrointestinal, IBS = irritable bowel syndrome, MCV = mean corpuscular volume, PDS = post-prandial distress syndrome.
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Autoimmune gastritis (AG) is a chronic disease occurring in up to
8%of the general population.[1] This condition is characterized by
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1intrinsic factor production, and, in a later stage, pernicious anemia.
Often, the positivity of autoantibodies against parietal cells and/or
intrinsic factor, the co-presence of autoimmune diseases as thyroid
autoimmune disease or type 1 diabetes are associated.[2–5]
Histologically AG is characterized by gastric body atrophy, defined
as replacementofoxyntic glandsbymetaplastic pyloric or intestinal
glands according to the updated Sydney System.[6]
A frequent clinical presentation of AG is pernicious anemia, a
megaloblastic anemia arising from vitamin B12malabsorption as a
consequence of intrinsic factor deficiency,[7,8] or the iron deficiency
anemia due to iron malabsorption as a consequence of reduced
gastric acid secretion together with normal or low cobalamin
levels[9] and some of these patients may over time develop overt
pernicious anemia.[10] Less frequently, the suspicion of AG arise
from the presence of gastrointestinal (GI) symptoms. From the GI
point of view, the clinical spectrum of AG has been traditionally
considered almost silent, even if the occurrence of symptoms in this
population has been reported, but risk factors for GI symptoms
associations in AG have not be established.[11–13]
The aim of this study was to assess in a large cohort of AG
patients the occurrence and pattern of GI symptoms and to
evaluate whether AG patients with GI symptoms are character-
ized by specific clinical features.
2. Methods
2.1. Patients and study design
A cohort of 379 consecutive AG patients, diagnosed from 1995
to 2013 in a tertiary referral center, was analyzed. Gastroscopy
[23]
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deficiency anemia, in 8.4% (32/379) for GI symptoms, in 2.9%
(11/379) for neurologic or endocrine disorders, in 2.9% (11/379)
for increased levels of gastrin, and 6.9% (26/379) for other
causes. Eventually proton pump inhibitors treatment was
withdrawn at least 2 weeks before gastroscopy.
The presence and the frequency of GI symptoms (heartburn,
regurgitation, early satiety, nausea, vomiting, postprandial
fullness, epigastric pain, abdominal pain, constipation, diarrhea,
and bloating) were assessed at the time of the first visit through a
standardized interview, according to a form that we have been
using for many years in our GI Department. Upper GI symptoms
were analyzed either separately or altogether to classify patients
in defined syndromes which may overlap. Gastro-esophageal
reflux disease (GERD) was defined by the presence of typical
reflux symptoms such as troublesome heartburn and/or regurgi-
tation at least once-2 times a week.[14] Dyspepsia was defined by
Criteria of Rome III for functional disorders, by the presence of
symptoms thought to originate in the gastroduodenal region,
with symptoms onset at least 6 months before.[15] This was
further subdivided in the postprandial distress syndrome (PDS) in
the presence of bothersome post-prandial fullness and/or early
satiation at least several times per week and epigastric pain
syndrome (EPS) in the presence of pain or burning localized in the
epigastrium and not associated with other abdominal or chest-
related symptoms, at least once per week for the last 3 months.
Since the study dealt with patients affected by AG, PDS and EPS
dyspepsia will be indicated as PDS- and EPS-like throughout this
article. In the presence of lower GI symptoms, patients were
categorized as having the irritable bowel syndrome (IBS), further
subdivided into diarrhea-predominant IBS (IBS-D), constipation-
predominant IBS (IBS-C), or mixed stool pattern IBS (IBS-M),
functional constipation, functional diarrhea, and functional
bloating following Rome III Criteria.[16] In the presence of
abdominal pain and without symptoms to meet criteria for other
functional GI disorder that could explain the pain, the diagnosis
of functional abdominal pain syndrome, following RomeCriteria
was made.[17] Informed consent was obtained from each
participant. For this cross-sectional study, an ethical approval
was not requested.Table 1
Clinical features of patientswith autoimmunegastritiswith respect
to the presence or the absence of gastrointestinal symptoms.
Absence of
gastrointestinal
symptoms n=164
Presence of
gastrointestinal
symptoms n=215 P
Female gender 104 (63.4) 162 (75.3) 0.01
Age, y, median, range 57 (17–83) 53 (22–80) 0.01
Smoking habit 39 (23.8) 33 (15.3) 0.04
Pernicious anemia 102 (62.2) 101 (47) <0.001
Iron deficiency anemia 51 (38.6) 81 (61.4) 0.22
Gastric autoantibodies
∗
111 (67.7) 144 (67) 0.97
Autoimmune disorders 68 (41.4) 90 (41.9) 0.98
Helicobacter pylori infection 41 (25) 58 (27) 0.75
When not otherwise indicated, data are expressed as the total number (percentage).
∗
Autoantibodies against parietal cells and/or intrinsic factor.2.2. Diagnosis of autoimmune gastritis, Helicobacter
pylori, and autoimmune status
AG has been defined on the basis of the concomitant presence of
fasting hypergastrinaemia, low pepsinogen I level, histological
confirmation of body atrophy, positivity to antiparietal cells, and/
or intrinsic factor antibodies and/or compresence of other
autoimmune diseases as previously reported.[18] The anemia
pattern was assessed by evaluating hemoglobin, mean corpuscu-
lar volume (MCV), ferritin, and vitamin B12 values. Pernicious
anemia was defined as the low hemoglobin concentration,
MCV>100 fl together with low B12 vitamin levels, responding to
intramuscular B12 vitamin treatment. Iron deficiency anemia was
defined as the low hemoglobin concentration, MCV< 80 fl, and
ferritin<30ng/mL.[19,20] Antiparietal cells’ antibodies were
evaluated on serum using a solid-phase immunosorbent assay
commercial kit (Autostat, Cogent Diagnostic Ltd, Edinburgh,
UK)[21,22] and antibodies against intrinsic factor were assessed
using a commercial kit (Quanta Lite, INOVA Diagnostics, San
Diego, CA).[19] Diagnosis of H pylori infection was assessed on
the basis of the bacteria evident at histological examination
(Giemsa stain) together with infiltration of polymorphonuclear2cells in gastric mucosa. The diagnosis of autoimmune thyroid
and extrathyroid disease was assessed as previously described.[5]2.3. Statistical analysis
Data were expressed as percentage (%) of total, or median
(range). Univariate analyses were performed by Mann–Whitney
and Fisher’s exact tests for categorical and continuous variables
in order to identify clinical differences between symptomless and
symptomatic patients. Odds ratio (OR) and 95% confidence
intervals (CIs) were used to describe associations and were
obtained by logistic regression analysis. Two-tailed P values
<0.05 were considered statistically significant. The statistical
analysis was carried out using a dedicated software package
(MedCalc Software, Mariakerke, Belgium, version 12.2).3. Results
Of the 379 patients included, 70.2% (n=266) were female, with
a median age of 55 years (17–83 years). Smoking habit was
present in 19% (n=72) of patients. Clinical features associated to
AG were: pernicious anemia (53.6%), iron deficiency anemia
(34.8%), presence of gastric autoantibodies (anti-parietal cell
and/or anti-intrinsic factor) (67.3%), autoimmune disorders
(41.7%), and H pylori infection (26.1%). Concerning autoim-
mune disorders, 89% of AG patients had thyroid disorders and
11% had 1 or 2 associated extra-thyroid diseases (i.e., vitiligo,
alopecia, diabetes, rheumatoid arthritis, hemolytic anemia,
Sjögren’s syndrome, psoriasis, autoimmune hepatitis, and
myasthenia). None of the patients had GI cancer at the time of
AG diagnosis. Polypharmacy (use of more than 2 drugs) was
present in 5.5% (n=21) of patients for common conditions such
as cardiovascular diseases, dyslipidemia, diabetes, and osteopo-
rosis. Prokinetics were taken by 6.6% (n=25) of patients.3.1. Occurrence of GI symptoms
One or more GI symptoms were present in 56.7% (n=215) of
AG patients. Table 1 shows the clinical features of AG patients
with respect to the presence or the absence of GI symptoms.
Females were significantly prevalent, about 10%more, among
the patients with GI symptoms compared to those without.
Symptomatic patients were significantly younger, about 5 years,
and more often no smokers, about a third less, in comparison to
the asymptomatic ones. Pernicious anemia was significantly more
Figure 1. Severity degree of gastric atrophy in symptomatic and asympto-
matic autoimmune gastritis patients. pts=patients.
Table 2
Clinical predictive factors associated to upper gastrointestinal
symptoms in patients with autoimmune gastritis.
Upper gastrointestinal symptoms Dyspepsia PDS-like
OR 95% CI OR 95% CI
Female gender 1.3 0.7–2.1 1.5 0.9–2.5
Age (<55 y) 1.8 1.1–2.8 1.6 1.0–2.5
No smoking habit 1.9 1.1–3.5 2.2 1.2–4.05
No anemia 2.6 1.3–5.5 3.1 1.5–6.4
CI=confidence interval, OR= odds ratio, PDS=postprandial distress syndrome.
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comparison to the symptomatic group. No differences were
found between symptomatic and asymptomatic patients con-
cerning the presence of iron deficiency anemia, positivity to
gastric autoantibodies, prevalence of H pylori infection, and the
concomitant presence of autoimmune disorders. The Sydney
score of corporal atrophy was evaluated in patients with and
without GI symptoms. As shown in Fig. 1, the distribution of
mild, moderate, and severe corporal atrophywas not significantly
different between the 2 groups of AG patients.
3.2. GI symptomatic pattern
Figure 2 illustrates the GI symptoms complained by AG patients.
Among symptomatic patients, the large part had exclusively
upper GI symptoms (n=150) and a smaller part complained
respectively only lower GI symptoms (n=34) or concomitant
upper and lower GI symptoms (n=31).
Analyzing all patients with upper GI symptoms (n=181),
60.2% (n=109) reported PDS-like dyspepsia, 3.8% (n=7) EPS-
like dyspepsia, 7.2% (n=13) overlap PDS and EPS-likeFigure 2. Symptomatic pattern of autoimmune gastritis patients. Black=only
lower gastrointestinal symptoms, Gray=combined of upper and lower
gastrointestinal symptoms, White=only upper gastrointestinal symptoms.
3dyspepsia, 7.2% (n=13) GERD, 17.7% (n=32) GERD and
dyspepsia, and 3.8% (n=7) nausea and/or vomiting. Among all
patients with lower GI symptoms (n=65), 27.7% (n=18)
reported the functional abdominal pain syndrome, 3.1% (n=2)
IBS-C, 3.1% (n=2) IBS-D, 16.9% (n=11) IBS-M, 21.5% (n=
14) functional constipation, 12.3% (n=8) functional diarrhea,
and 15.4% (n=10) functional bloating.
Logistic regression analysis was performed in order to assess
the presence of clinical features associated to the presence of
upper GI symptoms in AG patients, which resulted to be more
frequent in the study population (Table 2). This analysis showed
that the younger age (<55 years), the absence of smoking habit,
and the absence of anemia were independent factors associated to
the presence upper GI symptoms in AG patients. The positive
association between the absence of anemia and the presence of GI
symptoms was confirmed when the absence of pernicious anemia
(OR 2.4 [95%CI: 1.2–5.2]) and iron deficiency anemia (OR 3.1
[95%CI: 1.4–6.8]) was separately considered. When the presence
of PDS-like dyspepsia in AG patients was considered as the
dependent variable, the positive association with the same
independent variables was shown (Table 2).4. Discussion
This study aimed to investigate, in a large cohort of AG patients,
the occurrence and the pattern of GI symptoms and the presence
of specific clinical features that could represent a risk factor for
symptoms’ association. We demonstrated that more than half of
AG patients have 1 or more GI symptoms. The major part (about
70%) of symptomatic AG patients complained of upper GI
symptoms, in particular PDS-like dyspepsia characterized by
post-prandial fullness and/or early satiation, which were the most
frequent symptoms reported. Among the upper GI symptoms
reported, a quarter was represented by GERD, alone or
associated to dyspepsia. Despite the impaired acid secretion
occurring in AG due to atrophy of the oxyntic mucosa, it is
possible that nonacidic refluxes might develop and play as
determinants of heartburn perception, as recently observed.[24] In
fact, in a recent paper, Tenca et al[13] demonstrated that 24% of
AG patients present gastroesophageal reflux at pH-impedence
monitoring, irrespective of the presence of symptoms, confirming
that reflux can occur in AG patients. In another study by Miceli
et al,[11] it has been reported that 24% of AG patients complained
of heartburn and 12% of acid regurgitation. In addition, we
recently describe a case of Barrett’s esophagus in a patient
affected by pernicious anemia, supporting that GERD and its
related complications may originate even in a hypochlorhydric
patient.[25]
In our population, about 16% and 14% of the symptomatic
AG patients complained only of lower GI symptoms or of
concomitant upper and lower GI symptoms, respectively. The
Carabotti et al. Medicine (2017) 96:1 Medicineproportion of patients who had concomitant upper and lower GI
symptoms was lower among our AG patients than that reported
in patients with functional dyspepsia in which the overlapping
has been shown to be about 30%.[26,27] This data might support
the hypothesis that dyspepsia associated to AG is quite different
from functional dyspepsia.
It is known that dyspepsia is one of themost prevalent upper GI
disorders in the general population, and its prevalence is reported
to be about 20%.[15] In our cohort of AG patients, the prevalence
of dyspepsia is about 2 times higher than that expected in the
general population, suggesting a potential role of this condition in
the arising of this symptom. A former study conducted by Miceli
et al[11] reported in 99 patients with AG, frequencies of
postprandial fullness, and early satiety of 7.1% and 10.1%,
respectively.[11] These figures seem much lower compared to
those observed in our study. In the study by Soykan et al,[12]
46.7% of AG patients present abdominal symptoms, mainly
characterized by abdominal bloating and pain, with a minor part
complained of upper symptoms such as nausea and belching. It is
possible that discrepancy between our results and the previously
studies is mainly related to the different method used to collect
symptoms.
Although the roles of many pathophysiological factors have
been proposed in dyspepsia (i.e., altered gastro-duodenal
motility, visceral hypersensitivity, H pylori infection, acid
secretion, genetic, psychosocial, and lifestyle factors), the
underlying mechanism remains unclear. Previously, in atrophic
gastritis, a role of gastric emptying has been investigated,
showing a delayed emptying both in the autoimmune[28] and
nonautoimmune atrophic gastritis.[29] In addition, the reduced
gastric acid secretion seems to be associated with the presence of
dyspepsia[30] and more recently, a Japanese study conducted on
dyspeptic outpatients showed that hypochlorhydria was signifi-
cantly associated with higher dyspeptic symptom scores and
dysmotility-related scores, in particular, in female.[31]
In a systematic review evaluating the effects of proton pump
inhibitors on gastric emptying, a consistent delaying effect of
these drugs on gastric emptying of solid meals has been
shown.[32] Albeit the hypochlorhydria induced by proton pump
inhibitors does not perfectly overlap the intragastric milieu of
AG, these data seem to support the biological plausibility that the
impaired gastric acid secretion might have a role in generating the
dyspeptic symptoms, frequently present in AG.
Our results show that no relation between histological severity
of oxyntic damage and the symptoms’ presence as shown in
Fig. 1. However, we have to keep in mind that a close relationship
between the degree of histological oxyntic damage and acid
output has not been demonstrated, but the hypochlorhydria per
se, as previously reported, should justify the occurrence of
dyspeptic symptoms[31] as reported in our study.
Dyspepsia is a chronic condition, which affects quality of life of
patients, and it requires an early correct assessment in order to
avoid unnecessary medical visits and repetition of unnecessary
gastroscopy.[33] Even if AG patients complain of GI symptoms,
the clinical suspicion of AG is rarely raised on the basis of GI
symptoms, even when dyspepsia is present. In our study, even if
more than half of patients reported GI symptoms, less than a
tenth underwent gastroscopy for GI symptoms.
Comparing patients with and without GI symptoms, the
multivariate analysis shows that younger age, no smoking, and
absence of anemia are factors associated to the presence of upper
GI symptoms, particularlydyspepsia.On the contrary Soykanet al,
[12] did not find any significant difference in terms of age, gender,4autoimmune diseases, andpresence of gastric autoantibodieswhen
compare AGpatients with orwithout symptoms.[12] Thismight be
importantbecause clinical guidelines recommendgastroscopywith
biopsies for dyspeptic patients over the age of 55 years and for
patients with alarm symptoms (i.e., anemia),[34] and younger
dyspeptic patients without anemia generally are not referred to
gastroscopy, thus possibly missing the diagnosis of AG.
We are aware of some limits of this study. The study was
performed in an academic tertiary level center. This may have led
to possible selection bias. The study population is representative
of the population of Southern Europe, where the study has been
performed. For these reasons, the results of this study possibly
might not to be extended to the general population.
In conclusion, more than half of AG patients complained of GI
symptoms, in particular, dyspepsia, alone in 70%or associated to
GERD in 17.7% of symptomatic patients, confirming the
significant occurrence of symptoms in this population. In
autoimmune gastritis patients, the demonstrated association
between early satiety and postprandial fullness with younger age,
no smoker and not anemic status should be kept in mind in the
work-up of these patients.Acknowledgment
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